# Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

> **NCT06153420** · PHASE2 · TERMINATED · sponsor: **CinPhloro Pharma, LLC** · enrollment: 421 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** CIN-103
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06153420
- **Lead sponsor:** CinPhloro Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-28
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 421 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of efficacy compared to placebo.
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153420, "Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06153420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*